Login or sign up
For business

ImMAGE Biotherapeutics

3.9· 10 reviews
Average ratingAverage
3.9/ 5

Based on 10 reviews

530%
430%
340%
20%
10%
Ask AI

Ask Trustburn about ImMAGE Biotherapeutics

Based on 10 reviews on Trustburn

AI-generated from reviews on this page. Verify anything important with the company directly.

Socrates Nicholas
Reviews 1

I had a great experience with ImMAGE Biotherapeutics. Their website is user-friendly and provides all the necessary information about their products and services. The quality of their biotherapeutics is excellent, and their customer support team is very helpful. I highly recommend ImMAGE Biotherapeutics!

Kassandra
Reviews 1

I am impressed with the products and services provided by ImMAGE Biotherapeutics. The company has a well-designed website that is easy to navigate and has all the necessary details about their offerings. The quality of their biotherapeutics is top-notch. Highly recommended!

News

No news yet. This is where the business shares its own updates and press.

Photos

No photos yet. Photos shared by reviewers will show up here.

Widgets

Boost your business trust by displaying a widget on your website — a simple way to convert your visitors into customers.

Get the widget for your site →

About ImMAGE Biotherapeutics

Immage Biotherapeutics Corp. (OTC: IMMG) has been founded on the foundational understanding that many cancers can be treated via the harnessing the power of the human immune system. The pipeline of the company consists of a DNA viral vaccine construct that is target to tumors that expresses the Melanoma antigen family – A (MAGE-A) antigen.

The company has a pipeline of therapeutics that has a high success probability because our treatment targets patient population medical needs are not being met at this time. Our leading pipeline is a universal vaccine that can be used for any tumor that expresses tumor antigen MAGE-A. This treatment can be targeted to cancers that has a high expression of the MAGE-A antigen including, breast, colon, pancreas, glioblastoma, and esophageal squamous cell carcinomas, for example. The company expects to focus on developing the treatment for triple negative breast cancer.